Under EU regulations governing fungi, seemingly small technical distinctions can have significant implications for how products are classified, marketed and sold.
The species used, part of the organism included, production process, extraction method and even the specific strain can all influence whether an ingredient can be legally marketed in the EU.
For brands developing products with international ambitions, these considerations are best addressed at the formulation stage to avoid costly reformulations, according to Robin Gurney, founder of the Estonia-based organic mushroom ingredients and finished products brand Musheez.
“If a brand develops first for the relatively flexible U.S. market and considers Europe only afterwards, it may discover that key fungal ingredients need to be replaced before the product can cross the Atlantic,” he said, noting that formulators should consider European regulatory requirements from the outset of product development.
“Species matters. Fungal part matters. Processing matters. Sometimes strain matters. Get those decisions right at the beginning and there is enormous room to innovate.”
Specificity in sourcing
One of the most common misconceptions in the category is that a mushroom’s fruiting body and its mycelium are interchangeable from a regulatory perspective.
Under EU Novel Food rules, a history of consumption for a mushroom fruiting body (the part which grows above ground) does not automatically establish a history of consumption for its mycelium (root-like structure of a fungus).
“In a series of consultations involving species including shiitake, lion’s mane, reishi, maitake and king trumpet, Spanish authorities concluded that equivalence between the reproductive and vegetative parts of fungi could not simply be assumed in terms of nutritional composition, metabolites and active substances,” Gurney explained.
As a result, several mycelium-derived ingredients from species that are otherwise well-established edible mushrooms have been classified as Novel Foods in Europe.
This means that identifying an ingredient as “lion’s mane” or “reishi” is only the starting point. Regulators also need to understand which fungal part was used, how it was produced, whether it has been extracted or concentrated, the manufacturing process and possibly the specific strain.
Fruiting bodies offer a more direct root
Recent European Commission consultations have determined that specified fruiting-body extract powders from mushrooms such as lion’s mane, reishi, shiitake and maitake are not considered Novel Foods under certain conditions.
The key principle is that non-concentrated water extracts of non-novel foods generally retain their non-novel status provided that processing has not resulted in significant compositional changes.
That does not mean every extract is automatically acceptable. Extraction method, concentration levels and source material remain important. However, conventional fruiting-body powders and water extracts often provide a clearer regulatory pathway than novel mycelial ingredients.
“For lion’s mane, reishi and shiitake, the possible direction for an EU-oriented formulation is therefore relatively straightforward: Use properly documented fruiting-body material or an appropriate water extract rather than the novel mycelial component,” Gurney said.
This creates a practical consideration for ingredient selection: Where multiple ingredient options available, fruiting-body materials may offer a more predictable path to market in Europe.
Cordyceps get complex
Switching from mycelium to fruiting body is not always sufficient to resolve Novel Food concerns. In some cases, such as Cordyceps militaris, both forms remain subject to regulatory restrictions.
Cordyceps presents a more complex regulatory picture, with species, production methods and ingredient formats potentially falling under very different regulatory classifications. Gurney, however, noted that an alternative regulatory pathway may be available for certain cordyceps ingredients used in food supplements.
“Samsoniella hepiali is the organism associated with material widely known and marketed as Cordyceps sinensis Cs-4, or simply Cs-4, he said. “The EU Novel Food Catalogue was updated in 2025 to recognize S. hepiali as not novel for food supplement use.”
Cs-4 is a fermented mycelium material produced through liquid fermentation, after which the mycelium is harvested and dried to powder. That powder can also undergo further extraction.
“For a European food supplement, an appropriately identified and documented Cs-4 fermented mycelium powder or extract could therefore potentially replace C. militaris while retaining a cordyceps component.”
He further noted the food supplement distinction is important and should not automatically be extended to conventional foods or drinks.
Less clear cut for turkey tail
Turkey tail (Trametes versicolor) does not currently benefit from the same level of regulatory clarity enjoyed by other species.
“Turkey tail continues to appear in European Commission reporting among ingredients identified as not authorized in EU food supplements; for a formulation intended for the EU today, the practical option may therefore simply be to leave turkey tail out unless an authorized route can be established,” Gurney said, noting that this still leaves plenty of scope for a sophisticated multi-mushroom formulation.
“Choose established food mushroom species where possible,” he advised. Know whether you are using fruiting body or mycelium. Use appropriately documented water extracts where they offer the clearest route. Check food-specific and supplement-specific restrictions before the formulation is locked. ”




